Autonomy of Cortisol Secretion in Clinically Silent Adrenal Incidentaloma

Recent progress in non-invasive imaging techniques have resulted in an increasing frequency of adrenal incidentaloma discovery. In addition, even clinically silent adrenal tumor has been suggested to possess a subtle production of adrenal hormones. The aim of the study was to ascertain the autonomy of cortisol production in clinically silent adrenocortical incidentaloma. We investigated the hypothalamic-pituitary-adrenal axis in 38 patients with adrenal incidentaloma. Basal plasma cortisol level was reproducibly within normal range in all the patients with adrenal incidentaloma, but was also normal in half of the Cushing’s syndrome cases studied. Eighteen of 38 patients showed plasma cortisol above 3 µg/dl after 1 mg dexamethasone (Dex) and above 1 µg/dl after 8 mg Dex, respectively, and were defined as preclinical Cushing’s syndrome. These patients were subjected to further evaluation of the autonomy of cortisol production. The incidence of positive findings indicating autonomy of cortisol secretion was as follows: suppressed basal plasma ACTH level in 44 %, loss of normal diurnal rhythm in 79 %, lack of ACTH response to CRF in 35 %, decreased plasma DHEA-S level in 28 %, significant laterality of ¹³¹I-adosterol uptake in 75 %, atrophy of the contralateral side of the adrenal on CT scan in 6 %, and histological atrophy of the adjacent adrenal cortex in 56 %, respectively. The endocrine feature relevant to the hypothalamic-pituitary-adrenal axis varied from patient to patient, ranging from the non-functioning adrenal adenoma to Cushing’s syndrome. In addition, the results of each test did not coincide with others in each patient. These results clearly demonstrated that the incidence of autonomy of cortisol production in the clinically silent adrenal incidentaloma is not infrequent, showing significant diversity. Systemic evaluation of the hypothalamic-pituitary-adrenal axis before adrenal surgery is warranted for an appropriate glucocorticoid replacement after adrenal surgery.

Key words:

Cortisol - Cushing’s Syndrome - Autonomy - Preclinical Cushing’s Syndrome - Non-Functioning Adrenal Adenoma - Cortisol

References

• 1 Seddon J M, Baranetsky N, Van Boxel P J. Adrenal “incidentalomas”. Need for surgery.  Urology. 1985;  25 1-7
• 2 Herrera M F, Grant C S, van Heerden J A, Sheedy P F, Ilstrup E M. Incidentally discovered adrenal tumors: an institutional perspective.  Surgery. 1991;  110 1014-1021
• 3 Charbonnel B, Chatal J F, Qzanne P. Does the corticoadrenal adenoma with “pre-Cushing’s syndrome” exist?.  J Nucl Med. 1981;  22 1059-1061
• 4 Bertagna C, Orth D N. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978).  Am J Med. 1981;  71 (5) 855-875
• 5 Bogner U, Eggens U, Hensen J, Oelkers W. Incidentally discovered ACTH-dependent adrenal adenoma presenting as “pre-Cushing’s syndrome”.  Acta Endocrinol (Copenh). 1986;  111 89-92
• 6 Reincke M, Nieke J, Krestin G P, Saeger W, Allolio B, Winkelmann W. Preclinical Cushing’s syndrome in adrenal “incidentalomas”: comparison with adrenal Cushing’s syndrome.  J Clin Endocrinol Metab. 1992;  75 826-832
• 7 McLeod M K, Thompson N W, Gross M D, Bondeson A G, Bondeson L. Sub-clinical Cushing’s syndrome in patients with adrenal gland incidentalomas. Pitfalls in diagnosis and management.  Am Surg. 1990;  56 398-403
• 8 Terzolo M, Osella G, Ali A, Borretta G, Cesario F, Paccotti P, Angeli A. Subclinical Cushing’s syndrome in adrenal incidentaloma.  Clin Endocrinol (Oxf). 1998;  48 89-97
• 9 Rosen H N, Swartz S L. Subtle glucocorticoid excess in patients with adrenal incidentaloma.  Am J Med. 1992;  92 213-216
• 10 Osella G, Terzolo M, Borretta G, Magro G, Ali A, Piovesan A, Paccotti P, Angeli A. Endocrine evaluation of incidentally discovered adrenal masses.  J Clin Endocrinol Metab. 1994;  79 1532-1539
• 11 Huiras C M, Pehling G B, Caplan R H. Adrenal insufficiency after operative removal of apparently nonfunctioning adrenal adenomas.  JAMA. 1989;  261 894-898
• 12 Shealy C N. A review of dehydroepiandrosterone (DHEA).  Integr Physiol Behav Sci. 1995;  30 308-313
• 13 Gallagher T F, Yoshida K, Roffwarg H D, Fukushima D K, Weitzman E D, Hellman L. ACTH and cortisol secretory patterns in man.  J Clin Endocrinol Metab. 1973;  36 1058-1068
• 14 Nakahara M, Shibasaki T, Shizume K, Kiyosawa Y, Odagiri E, Suda T, Yamaguchi H, Tsushima T, Demura H, Maeda T, et al. Corticotropin-releasing factor test in normal subjects and patients with hypothalamic-pituitary-adrenal disorders.  J Clin Endocrinol Metab. 1983;  57 963-968
• 15 Hermus A R, Pieters G F, Smals A G, Benraad T J, Kloppenborg P W. Plasma adrenocorticotropin, cortisol, and aldosterone responses to corticotropin-releasing factor: modulatory effect of basal cortisol levels.  J Clin Endocrinol Metab. 1984;  58 187-191
• 16 Reincke M. Subclinical Cushing’s syndrome.  Endocrinol Metab Clin North Am. 2000;  29 (1) 43-56
• 17 Kloos R T, Gross M D, Francis I R, Korobkin M, Shapiro B. Incidentally discovered adrenal masses.  Endocrine Review. 1995;  16 460-484
• 18 Ishizuka T, Daidoh H, Morita H, Mune T, Miura A, Suwa T, Shibata T, Yamada K, Itaya S, Kajita K, Yasuda K. ACTH-induced cortisol secretion is mediated by cAMP and PKC in various adrenocortical adenomas.  Endocr J. 1997;  44 661-670
• 19 Reincke M, Beuschlein F, Menig G, Hofmockel G, Arlt W, Lehmann R, Karl M, Allolio B. Localization and expression of adrenocorticotropic hormone receptor mRNA in normal and neoplastic human adrenal cortex.  J Endocrinol. 1998;  156 415-423
• 20 Bencsik Z, Szabolcs I, Kovacs Z, Ferencz A, Voros A, Kaszas I, Bor K, Gonczi J, Goth M, Kovacs L, Dohan O, Szilagyi G. Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in non selected patients with incidentally detected adrenal tumors.  J Clin Endocrinol Metab. 1996;  81 1726-1729
• 21 Dominguez-Gadea L, Diez L, Piedrola-Maroto G, Crespo A. Scintigraphic diagnosis of subclinical Cushing’s syndrome in patients with adrenal incidentalomas.  Nucl Med Commu. 1996;  17 29-32
• 22 Torlontano M, Zingrillo M, D’Aloiso L, Ghiggi M R, Cerbo A D, Scillitani A, Petracca-Ciavarella G, Liuzzi A. Pre-Cushing’s syndrome not recognized by conventional dexamethasone suppression-test in an adrenal “incidentaloma” patient.  J Endocrinol Invest. 1997;  20 501-504
• 23 Trzeciak W H, LeHoux J G, Waterman M R, Simpson E R. Dexamethasone inhibits corticotropin-induced accumulation of CYP11A and CYP17 messenger RNAs in bovine adrenocortical cells.  Mol Endocrinol. 1993;  7 206-213
• 24 Loose D S, Do Y S, Chen T L, Feldman D. Demonstration of glucocorticoid receptors in the adrenal cortex: evidence for a direct dexamethasone suppressive effect on the rat adrenal gland.  Endocrinology. 1980;  107 137-146
• 25 Kontula K, Pomoell U M, Gunsalus G L, Pelkonen R. Glucocorticoid receptors and responsiveness of normal and neoplastic human adrenal cortex.  J Clin Endocrinol Metab. 1985;  60 283-289